Venetoclax is a highly selective oral BCL-2 inhibitor that showed anticancer activity in BCL2-dependent leukemia and lymphoma cell lines and mouse xenograft models as well as in primary cells, both as a single agent and in combination [191,192,193,194]. This evidence concerns the gene BCL2 and leukemia.